SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Synact Pharma Expects Full-Study Topline Results in Q2 2027

Synact Pharma expects topline results from its full study during the second quarter of 2027.

AB

Related stories